𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

✍ Scribed by Ralph G. Zinner; Frank V. Fossella; Gregory W. Gladish; Bonnie S. Glisson; George R. Blumenschein Jr.; Vassiliki A. Papadimitrakopoulou; Katherine M.W. Pisters; Edward S. Kim; Yun W. Oh; Beverly O. Peeples; Zhishen Ye; Rafael E. Curiel; Coleman K. Obasaju; Waun K. Hong; Roy S. Herbst

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
125 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I-II study of docetaxel-ifosfami
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer
✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 96 KB

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≀2, n

Phase II study of pemetrexed disodium, a
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group
✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati